Reduction of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody by Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis.

Competing Interests: Conflicts of interest and sources of funding: T.K. has received speaking fees from Tanabe Mitsubishi, Kissei, and received grants and speaking fees from GlaxoSmithKline. H.H. has received speaking fees and/or honoraria from Pfizer, Nihon pharmaceutical, Taiho, and Novartis. H.T. has received speaking fees from Sanofi. H.S. has received fees from Pfizer, Bristol-Myers Squibb, Eli Lilly, Sanofi, Abbvie, GlaxoSmithKline, Chugai, UCB, Takeda, Astellas, and Daiichi-Sankyo. K.F. has received speaking fees, and/or honoraria from Tanabe Mitsubishi, Bristol-Myers Squibb, Eli Lilly, Chugai, Jansen, Pfizer, Ono, AbbVie, Ayumi, Astellas, Sanofi, Novartis, Daiichi Sankyo, Eisai, Asahi Kasei, Japan Blood Products Organization, and Kowa, and has received research grants from Tanabe Mitsubishi, Bristol-Myers Squibb, Eli Lilly, Chugai, AbbVie, Ayumi, Astellas, Sanofi, Eisai, Tsumura & Co, and Asahi Kasei. There is no funding to declare for the research.